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Abstract 
Purpose: Gastric cancer is the third leading cause of cancer-related death worldwide. From 1974-1975, 
patients who received gastric resection only had a 5-year survival rate of 15.3%.16 With the introduction 
of chemoradiotherapy, the 5-year survival rate increased to 23.2% from 1995-2001.16 One question 
which can be imposed is how necessary is neoadjuvant chemotherapy in addition to surgery compared 
to surgery then adjuvant chemoradiotherapy in improvement of 5-year survivability of a gastric 
adenocarcinoma.1  
Methods and Materials: 7 random control trials using neoadjuvant chemotherapy and 2 random control 
trials using adjuvant chemoradiotherapy were examined using a network meta-analysis to determine 
which was the more beneficial for 3-year, 5-year, and Overall Survival. Secondary outcome was to 
determine which caused more life-altering side effects 
Results: There was no statistical benefit found in the use of adjuvant chemoradiotherapy over the use of 
neoadjuvant chemotherapy. The 5-year and Overall mortality were consistently higher in the adjuvant 
chemoradiotherapy group, but the strength of data in the network meta-analysis was inconclusive. 
Conclusion: Further study the use of neoadjuvant chemotherapy plus surgery in the treatment of gastric 
adenocarcinomas in order to improve quality of life for the patients is recommended as well as further 
study of adjuvant chemoradiotherapy to improve survivability. 
 
 
 
 
                                                             
1 PICO question 
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Neoadjuvant Chemotherapy and Adjuvant Chemoradiotherapy in the Treatment of Gastric 
Adenocarcinomas 
Introduction 
Epidemiology 
Gastric cancer is the third leading cause of cancer-related death worldwide.1 From a global perspective, 
gastric cancer is the 4th most common cancer to be diagnosed among men and 5th most common among 
women. Developing countries have a higher incidence of gastric cancer and account for 70% of 
diagnosed cases. These countries also have a mortality rate 5-10% greater than developed countries like 
the United States. This is most likely due to inadequate access to the more contemporary treatments, 
such as neoadjuvant chemotherapy or adjuvant chemoradiotherapy2. Overall, the mortality of gastric 
cancer is declining. 
 There are a variety of risk factors which may increase the incidence of an adenocarcinoma 
(Appendix A). Environmental factors are believed to play one of the largest roles in the increase and 
decrease of gastric cancer. Dietary salt intake is associated with higher incidence and mortality.3 Light to 
moderate alcohol consumption poses a slight increase in risk for the development of gastric cancer, 
whereas heavy alcohol consumption (>4 drinks per day or 60g of alcohol per day) has a proven 
significant increase in the risk of development.4 Similar to most other cancers, tobacco use also plays a 
role; there is strong data which show an association between duration of cigarette use and the 
likelihood of development of gastric cancer.5 Fruits and vegetables are observed to be protective against 
gastric cancer. Two to five servings of fruits and vegetable per day has a proven positive impact; in fact, 
people who consume recommended amounts of fruits and vegetables over a 40-year period have 
almost a 30% less risk of gastric cancer.6,7 Increased vitamin C consumption has also been linked as 
protective against gastric cancer, although separating the effects, or lack thereof, of ascorbic acid from 
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H. pylori bacteria is difficult.6 Although these factors can increase the risk of development of gastric 
cancer, it can also be caused by an infectious etiology. 
 There are two known infectious causes of an increase in risk of the development of gastric 
cancer: H. pylori and Epstein-Barr virus (EBV). H.pylori is considered a class I carcinogen by the World 
Health Organization (WHO) for the development of cancer. There is an approximate 3% greater chance 
of developing a gastric adenocarcinoma after the development of an H. pylori infection.8 Additional risk 
is attributed to H. pylori because the same environmental factors which influence a gastric 
adenocarcinoma (increase the risk- high salt intake, cigarette use, alcohol consumption; decrease the 
risk- consumption of fruits and vegetables, increase in dietary Vitamin C) influence the effect of H. pylori 
in the same way, respectively.8 The specific mechanism of action of how the Epstein-Barr Virus affects 
gastric adenocarcinomas is unknown, but there is a correlation with the presence of the virus and those 
affected by gastric cancer; approximately 8% of gastric cancer are EBV carcinomas.9 
 There is also a genetic component which increases the risk of gastric cancer. A germline 
mutation of the CDH1 gene located on chromosome 16q22 carries an increase risk in the early 
development of gastric adenocarcinomas.10 Gastric cancer has also been linked to Lynch Syndrome 
families carrying the germline mutations MLH1 and MSH2.11 
Pathophysiology 
 Gastric cancer should not be recognized as a single disease, but rather a collection of individual 
diseases within a single organ. Since 1965, Lauren’s criteria is the most widely accepted and frequently 
used classification system of gastric cancer.12 Historically, the Lauren subtype system breaks down 
gastric cancer into diffuse and non-diffuse. More recently, a  3 subtypes have been identified: non-
cardia intestinal gastric cancer, diffuse gastric cancer, and proximal gastric cancer. Non-cardia intestinal 
gastric cancer has a multi-step progression affecting the body/antrum aspect of the stomach. It begins 
with chronic inflammation (usually caused by H. pylori) which produces a chronic gastritis. This leads to 
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intestinal metaplasia, and finally dysplasia. This type of gastric cancer affects males to females in the US 
at a 3:1 ratio, with Caucasians making up almost 60% of all patients.2  (what proportion of the gastric 
cancers fall into each of these subtypes?) 
 Diffuse gastric cancer is described as widespread thickening and rigidity of the gastric wall.10,13 
This type of cancer has no known precursor lesion and no association with chronic inflammation. Instead 
there is either a mutation or epigenetic silencing of the E-cadherin gene; CDH1 gene. E-cadherin is 
protein which mediates cell interactions and cell polarity by attaching to the cytoskeleton during 
mitosis. Without this protein, gastric cancer cells are able to dissociate from their matrix and 
metastasize. 
 Proximal gastric cancer effects the distal 1/3rd of the esophagus, the gastroesophageal junction, 
and the gastric cardia. It is commonly caused by gastroesophageal reflux disease (GERD) and has been 
linked to Barrett’s Esophagus. H. pylori infections tend to be protective of this type of cancer. The H. 
pylori infection reduces acid production and decreases the GERD’s effect. Originally this subtype of 
gastric cancer was grouped with non-cardia intestinal gastric cancer because of the presentation: 
chronic inflammation, then intestinal metaplasia, and finally dysplasia. Due to its reversed interaction 
with H. pylori, proximal gastric cancer has become its own subtype.2 
Approximately 10% of cancer-related deaths worldwide are linked to gastric cancer which has a high 
fatality to case ratio of 70%.2 Ove the last 30 years, the 5-year-survivablitily of gastric cancer has 
increased from approximately 10% to over 20%.14 This increase is most likely due to improvements in 
surgical techniques and advancements in chemotherapy. The standard of treatment for gastric cancer is 
a resection of the tumor. In the 1960s, chemotherapy and radiation were included to assist in the 
treatment of non resectable tumors. The standard of care with chemotherapies was initially an infusion 
of 5-fluorouracil, until the 1970s, when a 3 drug regimen of 5-fluorouracil, doxorubicin, and mitomycin 
(FAM) was found to have better efficacy.15 Since response rates with FAM were found to be as high as 
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50%, other chemotherapies began to be tested. Epirubicin, cisplatin, and continuous infusion of 5-
fluorouracil were found to have a response rate of approximately 71% as a post-operative adjuvant.15 
These successful treatments led to the belief that gastric adenocarcinomas are chemotherapy sensitive 
tumors, so research started on different modalities and timings of infusions. In Japan, neoadjuvant 
chemotherapy research has gained interest in order to increase the number of patients who may be 
offered a curative resection. In the United States, the addition of postoperative chemoradiotherapy to 
gastric resections has proven to improve the 5-year survival rate. From 1974-1975, patients who 
received gastric resection only had a 5-year survival rate of 15.3%.16 With the introduction of 
chemoradiotherapy, the 5-year survival rate increased to 23.2% from 1995-2001.16 One question which 
can be imposed is how necessary is neoadjuvant chemotherapy in addition to surgery compared to 
surgery then adjuvant chemoradiotherapy in improvement of 5-year survivability of a gastric 
adenocarcinoma.2  
Methods 
Literature Search 
A systematic literature search was done using the following databeases: Trip, Embase, Pubmed, 
CINAHL, and Google Scholar. The search terms used were “Gastric/stomach”, 
“cancer/carcinoma/adenocarcinoma”, “neoadjuvant/preoperative chemotherapy”, “adjuvant 
Chemoradiotherapy/radiation/chemotherapy”, “surgery/surgery alone”, and “5 year survival”.  The 
special database function “related articles” was used to maximize the search. The references from 
relevant articles and the randomized controlled trials used within the articles were searched to identify 
additional relevant articles. Due to the nature of the disease and the therapies provided, relevant data 
was acceptable from 2000 to current times. The records included 563 articles and after reviewed for 
duplicates, 552 articles remained.  The articles’ title and abstracts were screened for relevance on the 
                                                             
2 PICO question 
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topic and 37 remained. Of the 37 remaining articles, 11 studies were primarily used for the data in this 
report; 9 random controlled trials and a meta-analysis. The meta-analysis was chosen draw from the 7 
random controlled trials (RCT) used in its research. Only research translated to/written in the English 
languae were applied and the last data search done on August 4, 2018.  
Inclusion/Exclusion Criteria 
The articles were screened using the following criteria:  all articles were written or translated to 
English by the year 2000, all patients were diagnosed with gastric adenocarcinomas of the stomach or 
gastroesophageal junction which were histologically confirmed, resectable cancers only, no race or 
gender limitations, clear documentation of each intervention with procedure, only either preoperative 
chemotherapy or post operative chemotherapy with radiation were used in addition to a resection for 
the therapy groups, no chemotherapy or radiation were used with the control groups, no distant 
metasis were noted prior to randomization, the procedure must have complete resection of the 
carcinoma with margins <1cm, a response to each treatment was documented and the patients were 
categorized appropriately, and clear documentation of side effects from the medications were noted. 
Excluded articles with justification are listed in Appendix B. 
Data Collection Process  
All articles were examined by 1 author and then content and article relevance were reviewed by 
2 authors. This meta analysis is written in accordance to PRISMA guidelines, and the following data was 
extracted from each study: design from 10 RCTs, study population, and inclusion/exclusion criteria. 
Therapies of the studies were neoadjuvant chemotherapy (NAC) and adjuvant chemoradiotherapy 
(ACRT) listed in Table 317,18. No specific surgery was studied, as long as it met inclusion criteria. The 
diagnosis of gastric cancer was done in Xu et al in accordance with the 14th edition of the Union for 
International Cancer Control (UICC) tumor node metastatic (TNM) classification of malignant tumors and 
the Japanese Gastric Cancer Classification17,19. The diagnoses of gastric cancer were done in MacDonald 
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et al and Sung Kim et al in accordance with 1988 staging criteria of the American Joint Commission on 
Cancer18,20. Study population includes number of patients studied, race, age and gender. 
Determination of Bias 
Bias across this study was evaluated with the Cochrane Collaberation tool. High quality data was 
given a score of 4/5 or higher, medium quality data was given a score of 3/4, and low quality data was 
given a score of 2/4 or below. All studies will begin at 5 and will be deducted 1/2 of a point per qualified 
metric of bias. This will standardize the scoring system and assist in evaluation of quantified bias 
evaluation. These scoring assignments were determined before the study began. 
Results 
Selected trials 
Zero studies were identified which compared neoadjuvant chemotherapy to adjuvant 
chemoradiotherapy. The most appropriate way to compare the two therapies was determined to 
compare their effects versus a control (surgery alone) and then contrast the effectiveness of each 
therapy against each other using a network meta-analysis. The 9 RCTs evaluated began collecting data 
no later than 1991 and they were all published between 2000 and 2010, and they all followed patients 
for a minimum of 60 months each. Demographics and Therapies of each study are listed in Appendix 
C18,21–25. The main recorded demographic were T staging of the tumor, age range, and gender. Zhao et al. 
and Kobayashi et al. did not include an initial T staging due to the studies concentrating on gene 
expression of PCNA, Fas/FasL and PD-ECGF. The flow diagrams in Appendix F show how each RCT’s 
participation was enacted18,21–25. 
Primary Outcomes 
The primary outcomes of the trials were to assess the 3-year survivability (Table 1&2), 5-year 
survivability (Table 3&4) and Overall Mortality (Table 5&6) of the therapies.17,21,23–27 There was 
significant heterogeneity through out all of the studies, so a random effects model was chosen to 
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determine outcomes. No study out of the NAC group showed any statistically significant improvement in 
3-year mortality over surgery alone (RR 1.05, 95%CI 0.91,1.22). Nio, Schuhmaker, and Imano studies 
generally favored NAC, but the strength of data was low. Both studies out of the ACRT group showed 
favorable 3-year survivability in the therapy groups, but the favorablitity was minimal. The network 
meta-analysis (Table 2) shows a benefit of ACRT over NAC, but the benefit is not statistically significant. 
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No study out of the NAC group showed any statistically significant improvement in 5-year 
mortality over surgery alone (RR 1.02, 95%CI 0.91, 1.15). Schuhmaker, Imano, and Wang studies 
generally favored NAC, but the strength of data was low. Nio and Kobayashi showed practically no 
difference in outcomes for NAC versus SA. Both studies out of the ACRT group showed a favorable 5-
year survivability in the therapy groups, although the combined data proved to be not statistically 
significant (RR 1.42, 95%CI 0.87, 2.31). The MacDonald study’ therapy showed to be statistically 
significant benefitial by itself over surgery alone (RR 1.84, 95%CI 1.42, 2.40). The network meta- analysis 
(Table 4) once again favored ACRT over NAC, but there was no statistically significant benefit of either 
therapy. 
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No study out of the NAC group showed any statistically significant improvement in Overall 
Mortality benefit over surgery alone (RR 0.93, 95%CI 0.81, 1.08). Hartgrink and Kobayashi studies tended 
to favor surgery alone over NAC, while Wang and Zhao showed the most favor toward the therapy 
group. Both studies out of the ACRT group showed a favorable mortality benefit in the therapy groups 
(RR 0.81, 95%CI 0.71, 0.92). The MacDonald study showed the most statistically significant benefit in 
therapy over surgery alone (RR 0.76, 95%CI 0.68, 0.85). The network meta-analysis (Table 6) could not 
prove a benefit to either therapy. 
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Secondary Outcome 
Side effects and adverse reactions due to therapy was the second outcome being evaluated. 
Due to the variety of therapies being used, heterogeneity remained a problem in the NAC group. ACRT 
had the most prevalence for post-operative complications with 49 patients suffering from toxicities 
which required treatments to stop and an additional 3 who died as a result from the treatment in the 
MacDonald et al. group 18. In the Sung Kim et al. study 101 patients could not complete ACRT due to 
adverse side effects and 217 patients expierenced a Grade 3 or 4 side effect, with 1 person dying as a 
result of therapy. The most common side effects of the ACRT were severe nausea, vomiting, diarrhea, 
and leukopenia which happened in over 40% of the patients. All other types of toxicities were in less 
NEOADJUVANT CHEMOTHERAPY VERSUS ADJUVANT CHEMORADIOTHERAPY 14 
 
 
than 10% of the population. These side effects included adhesive ileus, myelosuppression, sepsis, 
pulmonary fibrosis, intestinal fibrosis, hepatic events, pain, neurologic dysfunction, and cardiac events. 
The side effects varied between treatments for the NAC. Hartgrink reported 5 patients suffering from 
toxicity23. Nio recorded a total of 24 patients suffering from anorexia, leukopenia, thrombocytopenia, 
liver dysfunction, and massive GI bleeding from carcinoma21. Schuhmacher’s study reported 8 patients 
with more mild side effects such as renal toxicity, cardiac toxicity, nausea, vomiting, and diarrhea22. In 
contrast, Imano’s study recorded no toxicities25. The overall rate of side effects was 18% across all the 
NAC studies. 
Bias Evaluation 
The Cochrane Risk of Bias tool (Appendix D) was used to evaluate each study for individual bias 
and GRADE (Appendix E) was used to evaluate Bias across outcomes.17,18,21,23–25,27 Allocation and blinding 
were previously stated problems across all of the NAC studies17 Nio et al. had a high risk of selection bias 
due to inadequate generation of a randomised sequence and inadequate concealment of allocations 
prior to assignment. The article claims NAC cannot be done with randomization due to the possibility of 
postponing curative resection, therefore the patients determined if they were in the control or therapy 
group. Nio et al. also had an unclear risk of detection bias due to lack of blinding of the interventions to 
the providers and patients. The author did not address if this was a possible source of bias. Schumacher 
et al. has an unclear risk of other bias due to not histologically confirming the gastric cancer prior to 
treatment. Hartgrink et al has a high risk of selection bias due to inadequate randomization. The trial 
randomized their patients based on a rule out of the clinic where the therapy was conducted. Zhao et al. 
has an unclear risk of selection bias. The article states the patients were separated into 3 groups, but it 
does not say how they were selected into the groups or what randomization process was used. Wang et 
al. did not address their method to conceal allocation and they had a high risk of performance bias due 
to not blinding the participants or the providers. It was unclear if the patients were blinded in Kobayashi 
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et al. Also, the patients were told of the desired outcomes of each trial, so there is a high risk of 
detection bias. 
 Another source of bias was small numbers of patients draw inaccuracy of conclusions on 
Hartgrink, Zhao, Schumacher, and Imano17. There were several measurement bias noted throughout the 
studies. MacDonald had inclusion criteria for pre-operative major organ functions which were not 
present in any other study18. This could have affected the overall health of all the patients in the ACRT 
study. Every NAC therapy was different. This caused a heterogeneity between that group as a whole. 
Another source of measurement bias were the varieties of surgeries. Since no specific surgery was 
tracked, post-operation mortality could be due to an inadequate procedure. Although the NAC did 
specifically only entail gastric adenocarcinomas, the ACRT studies included gastro-esophageal junction 
adenocarcinomas as well. This may result in a higher mortality rate along with more severe side effects.  
Discussion 
The primary outcomes studied in this comparison was the effect on mortality on gastric 
adenocarcinomas of NAC vs ACRT. No statiscally significant benefit to either therapy could be 
determined throught the network meta-analysis. Although ACRT was statistically more beneficial in 5-
year and overall survival than surgery alone where NAC was not, the evidence was leaning toward a 
possibility that NAC may have had a benefit. This observation created the possibility that NAC may be as 
therapeutic in the survivial benefit as ACRT in the treatment of gastric adenocarcinomas.  
There were 2 main measurement biases which could have affected the outcomes of the trials. The 
first measurement bias noted was the inclusion criteria the ACRT study set for organ function prior to 
surgery. MacDonald AND Sung Kim made sure their patients had a certain level of health defined as18: 
1. creatinine concentration no more than 25 percent higher than the upper limit of normal 
2. hemogram within the normal limits 
3. bilirubin concentration no more than 50 percent higher than the upper limit of normal 
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4. serum aspartate aminotransferase concentration no more than five times the upper limit of 
normal 
5. alkaline phosphatase concentration no more than five times the upper limit of normal and this 
created a consistency in their participants. 
The NAC studies had no overall health of organ function criteria prior to initiation of therapy21–25. 
This may have created a benefit in 3-year survival for ACRT which would not have existed if all 
participants in all of the studies entered with the same criteria. The second measurement bias was the 
difference in surgeries. D0, D1, and D2 lymphandectomy/gastrectomy were performed throughout the 
studies. The ACRT trial did not specify which type of gastrectomy was being performed. As previously 
stated Hartgrink underperformed in the 3-year period, and all the patients underwent a D1 
gastrectomy23. This under-performance could then be attributed to the delay in a curative surgery and 
causing a further progression of the disease or the ACRT could have used a D2 surgery and had an 
immediate curative effect. Also, the ACRT study included gastroesophageal junction adenocarcinomas, 
whereas the NAC studies did not18. This may have increased probability of overall mortality of the 
patients in the ACRT group prior to the start of the study. Heterogeniety in the NAC arm was also a 
contributing factor to the inconclusive data. None of the studies used exactly the same drugs, duration 
of therapy, or routes of administration; the most common NAC pharmacologic treatment being 
Fluorouracil used in 3 of the 7 RCT (see Appendix C). There were noted advantages and disadvantages of 
each NAC therapy. Hartgrink and Zhao’s therapies had inferior performance in the 3-year comparisons 
to the other studies23,24. Nio did show improvement over SA, but the improvement was statistically 
insignificant21. Imano’s study had the widest variants25. Overall the was no consistent data, or even a 
trend of consistent findings, between the NAC studies. 
The secondary outcome which was observed were the adverse reactions noted in each group. 
The adverse effects and patients withdrawing from studies was considerably lower in the NAC group (53 
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out of 411) compared to the ACRT (244 out of 825) 18,21–25. The surgeries and location of the cancers had 
little to do with the adverse reactions to the therapies administered. The overall health of the patients 
could be considered a bias with an unfair advantage given to the ACRT group, but NAC still out 
performed them. The NAC group did use different therapies, and this source of measurement bias may 
contribute the most to the strength of the evidence. Nio and Schumacher had the highest overall rate of 
notable toxicities, 23.5% and 32%, respectively, but they are still lower than the rate of toxicity from the 
MacDonald study (54%) or Sung Kim (34%)18,21,22. 
Overall the strength of the evidence is low to any advantage of survivability of a gastric 
adenocarcinoma with the use of neoadjuvant chemotherapy plus surgery or surgery then adjuvant 
chemoradiotherapy. There may be a correlation of evidence which reflects that neoadjuvant 
chemotherapy has less side effects and this may lead to a higher quality of life for the patients, but the 
survivability may also be lower. This data leads to a recommendation to further study the use of 
neoadjuvant chemotherapy plus surgery in the treatment of gastric adenocarcinomas in order to 
improve quality of life for the patients, and to further study adjuvant chemoradiotherapy to improve 
survivability. 
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Appendix A 
Cancer Overview 
 
 
Table 1     Trends in 5-Year Relative Survival Rates (%) by Race and Year of Diagnosis, United States, 1975 to 2007
All Races Caucasian African American
1975 to 
1977
1987 to 
1989
2001 to 
2007
1975 to 
1977
1987 to 
1989
2001 to 
2007
1975 to 
1977
1987 to 
1989
2001 to 
2007
All cancer 49 56 67 50 57 69 39 43 59
Nervous system 22 29 35 22 28 34 25 31 40
Breast (female) 75 84 90 76 85 91 62 71 77
Colon 51 60 65 51 61 67 45 53 55
Esophagus 5 10 19 6 11 20 3 7 13
Hodgkins Lymphoma 72 79 86 72 80 88 70 72 81
Kidney 50 57 71 50 57 71 49 55 68
Larynx 66 66 63 67 67 65 59 56 52
Leukemia 34 43 57 35 44 57 33 36 50
Liver and bile duct 3 5 15 3 6 15 2 3 10
Lung and bronchus 12 13 16 12 13 17 11 11 13
Melanoma of the skin 82 88 93 82 88 93 58 79 73
Myeloma 25 28 41 25 27 42 30 30 41
Non-Hodgkin Lymphoma 47 51 70 47 52 71 48 46 62
Oral cavity 53 54 63 54 56 65 36 34 45
Ovary 36 38 44 35 38 43 42 34 36
Pancreas 2 4 6 3 3 6 2 6 4
Prostate 68 83 100 69 85 100 61 72 98
Rectum 48 58 68 48 59 69 45 52 61
Stomach 15 20 27 14 19 26 16 19 27
Testicle 83 95 96 83 95 97 73 88 86
Thyroid 92 95 97 92 94 98 90 92 95
Urinary bladder 73 79 80 74 80 81 50 63 64
Uterine cervix 69 70 69 70 73 70 65 57 61
Uterine corpus 87 83 83 88 84 85 60 57 61
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Appendix B 
Excluded Articles 
The following articles were excluded due to use of additional therapies to neoadjuvant chemotherapy: 
1.  Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone 
for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20 
2. Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PW, Ajani JA, et al. A pilot study of preoperative 
chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol. 2001 Jul;8(6):519–524. 
3. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PWT, Crane CH, et al. Phase II trial of 
preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): 
quality of combined modality therapy and pathologic response. J Clin Oncol. 2006 Aug 
20;24(24):3953–3958. 
4. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. 
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N 
Engl J Med. 2006 Jul 6;355(1):11–20. 
 
The following articles were excluded due to use of only adjuvant chemotherapy without radiation: 
1. Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after 
D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 
2012;379(9813):315–321  
2. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial 
comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J 
Clin Oncol. 2011;29(33):4387–4393  
3. The GASTRIC group. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-
analysis.JAMA. 2010;303(17):1729–1737 
4. Di Costanzo F, Gasperoni S, Manzione L, et al. Adjuvant chemotherapy in completely resected 
gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 
2008;100(6):388–398 
5. De Vita F, Giuliani F, Orditura M, et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-
fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III 
trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol. 
2007;18(8):1354–1358 
6. Cirera L, Balil A, Batiste-Alentorn E, et al. Randomized clinical trial of adjuvant mitomycin plus 
tegafur in patients with resected stage III gastric cancer. J Clin Oncol. 1999;17(12):3810–3815  
7. Bajetta E, Buzzoni R, Mariani L, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of 
a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol. 
2002;13(2):299–307  
8. Coombes RC, Schein PS, Chilvers CE, et al. A randomized trial comparing adjuvant fluorouracil, 
doxorubicin, and mitomycin with no treatment in operable gastric cancer. International 
Collaborative Cancer Group. J Clin Oncol. 1990;8(8):1362–1369  
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9. Bouché O, Ychou M, Burtin P, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin 
compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III 
trial (8801). Ann Oncol. 2005;16(9):1488–1497 
10. Krook JE, O’Connell MJ, Wieand HS, et al. A prospective, randomized evaluation of intensive-
course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric 
cancer. Cancer. 1991;67(10):2454–2458 [ 
11. 24. Lise M, Nitti D, Marchet A, et al. Final results of a phase III clinical trial of adjuvant 
chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable 
gastric cancer. J Clin Oncol. 1995;13(11):2757–2763  
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and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric 
adenocarcinoma: a Southwest Oncology Group study. Ann Surg Oncol. 1995;2(6):488–494  
13. Nakajima T, Kinoshita T, Nashimoto A, et al. Randomized controlled trial of adjuvant uracil-
tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg. 
2007;94(12):1468–1476  
14. Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by 
oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer 
Surgical Study Group. Lancet. 1999;354(9175):273–277  
15. Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with 
mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-
negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003;21(12):2282–
2287  
16. Nitti D, Wils J, Dos Santos JG, et al. Randomized phase III trials of adjuvant FAMTX or FEMTX 
compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI 
Group and the ICCG. Ann Oncol. 2006;17(2):262–269 
The following articles were excluded due to unclear documentation of a D1/D2 surgery: 
1. Tsavaris NB, Tentas K, Kosmidis P, et al. 5-Fluorouracil, epirubicin, and mitomycin C versus 5-
fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A 
randomized trial. Am J Clin Oncol. 1996;19(5):517–521 
2. Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, Tanaka S, et al. Neoadjuvant 
chemotherapy for high-grade advanced gastric cancer. World J Surg. 1993 Mar;17(2):256–261. 
 
The following articles were excluded due to the abstracts being written in English, but the random 
controlled trials were only available in Japanese: 
1. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant 
chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999 
Mar;229(3):303–308.  
2. Lygidakis NJ, Sgourakis G, Aphinives P. Upper abdominal stop-flow perfusion as a neo and 
adjuvant hypoxic regional chemotherapy for resectable gastric carcinoma. A prospective 
randomized clinical trial. Hepatogastroenterology. 1999 Jun;46(27):2035–2038. 
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Appendix C 
Demographics and Therapies 
Study Demographics 
 
 
 
 
 
 
 
NAC ACRT
Hartgrink Nio Zhao Imano Schumacher Wang Kobayashi MacDonald Sung Kim
N 29 102 40 47 72 30 91 281 544
Age (yrs)
Median na 64 57.5 60 56 54 na 60 54
Range up to 75 51-75 32-70 46-72 38-70 37-65 up to 75 25-87 23-70
Male sex % na 70 69 69 69.4 76.7 na 72 65.5
T stage
T1 or T2 15 62 na 22 0 19 na 31 52.4
T3 4 15 na 25 68 11 na 62 44.3
T4 8 25 na 0 4 0 na 6 3.3
Location of primary tumor
Antrum 14 na na 6 na na na 53 261
Corpus 15 na na 8 na na na 24 227
Cardia 0 na na 28 na na na 21 48
Multicentric 0 na na 5 na na na 2 9
Thearpies During the Trials
Neoadjuvant Chemotherapy
PO Tegafur/uracil 7 mg/kg/d×21 d
DDP (50 mg/m2/d×3 d), d-L-folinic acid (500 mg/m2/d×6 d), 5-FU (2000 mg/m2/d×6 d); 2 courses; intravenous
IV methotrexate 1500 mg/m2 plus IV Fluorouracil 1500 mg/m2 plus leucovorin 30 mg/6 h×2 d plus doxorubicin 30 
mg/m2 for 4 courses
PO doxifluridine 800–1200 mg/d
or 
IV 500mg Fluorouracil plus Cisplatin/Fluorouracil 200 mg/d ×3–5 d
IV Fluorouracil 330 mg/m2/d×3 d
or 
IV Cisplatin 18 mg/m2 x 3d
or 
IV Cisplatin/Fluorouracil 200 mg/d ×3
PO Flourouracil 2x20ml/day, over 12.5 days, total dosing being 2g, oleic acid, ginseng polysaccharides, bean 
phosopholipids, and cholesterol
PO doxifluridine 610 mg/m2/d 6 10 d
Adjuvant Chemoradiotherapy
400 mg/m2 of fluorouracil plus 20 mg/m2 of leucovorin for 5 days, followed by 4,500 cGy of radiotherapy for 5 
weeks, with fluorouracil and leucovorin on the first 4 and the last 3 days of radiotherapy. Two 5-day cycles of 
fluorouracil and leucovorin were given 4 weeks after the completion of radiotherapy. The dose of fluorouracil was 
reduced in patients who had grade 3 or 4 toxic effects.
400 mg/m2 of fluorouracil plus 20 mg/m2 of leucovorin for 5 days, followed by 4,500 cGy of radiotherapy for 5 
weeks, with fluorouracil and leucovorin on the first 4 and the last 3 days of radiotherapy. Two 5-day cycles of 
fluorouracil and leucovorin were given 4 weeks after the completion of radiotherapy.
Kobayashi
MacDonald
Sung Kim
Nio
Schumacher
Hartgrink
Zhao
Imano
Wang
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Appendix D 
Cochrane Risk of Bias 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Random Sequence 
Generation
Allocation of 
Concealment Selective Reporting Other Bias
Blinding of Participants 
and Personnel
Blinding of Outcome 
Assessment
Incomplete Outcome 
Data
Nio - - + + - ? +
Schumacher + + + ? + + +
Hartgrink + - + + + + +
Zhao ? + + + + + +
Imano + + + + + + +
Wang + ? + + - + +
Kobayashi + + + + ? + +
MacDonald ? ? + - ? ? +
Sung Kim ? ? + - ? ? +
Key
Low risk of Bias +
High Risk of Bias -
Unclear risk of Bias ?
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Appendix E 
GRADE 
 
 
 
Question:
No of studies Design Limitations Inconsistencies Indirectness Imprecision Other Considerations NAC Surgery Alone
Relative Risk
(95% CI) Absolute
NAC's were not 
the same
Post operative illness 
confounding
Surgeries were 
not the same
Inclusion criteria 
of patients were 
not the same
NAC's were not 
the same
Post operative illness 
confounding
Surgeries were 
not the same
Inclusion criteria 
of patients were 
not the same
NAC's were not 
the same
Post operative illness 
confounding
Surgeries were 
not the same
Inclusion criteria 
of patients were 
not the same
2/5 Critical
Surgical 
complication 
confounding
All Purpose Mortality (# of deaths/participants)- NAC
7 randomized trials
Participants due 
to side effects of 
the therapies
direct
Staging of 
cancers before 
the study was 
done from 
different 
literature
175/411 191/441 0.93 (0.81, 1.08)
40 per 
1000 
people 
benefit 
from NAC 
over 
Surgery 
Alone
246/421 1.02 (0.91, 1.15)
17 per 
1000 
people 
benefit 
from NAC 
over 
Surgery 
Alone
2/5 Critical
Surgical 
complication 
confounding
2/5 Critical
Surgical 
complication 
confounding
5-Year Survivability- NAC
7 randomized trials
Participants due 
to side effects of 
the therapies
direct
Staging of 
cancers before 
the study was 
done from 
different 
literature
208/371
3-Year Survivability- NAC
7 randomized trials
Participants due 
to side effects of 
the therapies
direct
Staging of 
cancers before 
the study was 
done from 
different 
literature
179/290 212/331 1.05 (0.91, 1.22)
26 per 
1000 
people 
benefit 
from NAC 
over 
Surgery 
Alone
  How necessary is neoadjuvant chemotherapy in addition to surgery compared to surgery then adjuvant chemoradiotherapy in improvement of 5-
year survivability of a gastric adenocarcinoma?
Quality Assessment Summary of Finding
ImportanceNo of Patients Effect Quality
Question:
No of studies Design Limitations Inconsistencies Indirectness Imprecision Other Considerations ACRT Surgery Alone
Relative Risk
(95% CI) Absolute
Post operative illness 
confounding
Post operative illness 
confounding
Post operative illness 
confounding
  How necessary is neoadjuvant chemotherapy in addition to surgery compared to surgery then adjuvant chemoradiotherapy in improvement of 5-
year survivability of a gastric adenocarcinoma?
Quality Assessment Summary of Finding
ImportanceNo of Patients Effect Quality
3-Year Survivability- ACRT
2 randomized trials
Participants due 
to side effects of 
the therapies
direct None 511/825 381/721 1.15 (1.06, 1.25)
83 per 1000 
people 
benefit from 
ACRT over 
Surgery 
Alone
Critical
Surgical 
complication 
confounding
5-Year Survivability- ACRT
2 randomized trials
Participants due 
to side effects of 
the therapies
direct None 426/825
4/5 Critical
Surgical 
complication 
confounding
2 randomized trials
Participants due 
to side effects of 
the therapies
direct None 400/825
Surgeries were 
not the same
Surgeries were 
not the same
Surgeries were 
not the same
All Purpose Mortality (# of deaths/participants)- ACRT
436/721 0.81 (0.71, 0.92)
130 per 1000 
people 
benefit from 
ACRT over 
Surgery 
Alone
288/721 1.42 (0.87, 2.31)
123 per 1000 
people 
benefit from 
ACRT over 
Surgery 
Alone
3/5 Critical
Surgical 
complication 
confounding
4/5
NEOADJUVANT CHEMOTHERAPY VERSUS ADJUVANT CHEMORADIOTHERAPY 27 
 
 
Appendix F 
Random Control Trial Flow Diagrams 
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